GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

recaticimab   Click here for help

GtoPdb Ligand ID: 14196

Synonyms: Ai Xin'an® (China) | SHR-1209 | SHR1209
Approved drug
recaticimab is an approved drug
Compound class: Antibody
Comment: Recaticimab (SHR-1209) is an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody.
No information available.
Summary of Clinical Use Click here for help
Recaticimab was progressed as a clinical candidate for the treatment of hypercholesteremia and mixed dyslipidemia [2]. It was first approved in China in January 2025 for these indications [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04885218 Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd. The REMAIN-2 study 2
NCT04849000 Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd. The REMAIN-1 study 3